**Supplementary table2.** Objective response rate (ORR) and disease control rate (DCR) by RECIST v1.1

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Response category** | **All patients**  **(n = 18)** | **Patients with higher enhancement HCC nodules**  **(n = 8)** | **Patients with**  **hypointense HCC nodules**  **(n = 10)** | **P value** |
| ORR | 4 (22.2%) | 1 (12.5%) | 3 (30.0%) | 0.382 |
| DCR | 10 (55.6%) | 3 (37.5%) | 7 (70.0%) | 0.184 |
| CR | 0 | 0 | 0 |  |
| PR | 4 | 1 | 3 |
| SD | 6 | 2 | 4 |
| PD | 8 | 5 | 3 |

RECIST v1.1, the Response Evaluation Criteria in Solid Tumors version 1.1; ORR, objective response rate; DCR, disease control rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease

The ORR and DCR were compared between patients with higher enhancement HCC nodules and those without higher enhancement HCC nodules by Pearson’s chi-square test.